Audit: QRS - Beta-Sitosterol for Health & Longevity
Audit conducted on 20/09/2026 02:16 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 82 |
| Failed | 0 |
| N/A | 11 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked across all populated variables: protocol doses (ER line 320, 322, 326), time-to-effect (ER line 366), all nine monitoring rows and targets (ER lines 396–404), cadence (ER line 392), all six contraindications (ER lines 295–300), all ten interactions (ER lines 273–291), benefit and risk tier headings (ER lines 139–187, 207–257), six qualitative markers (ER lines 408–413). No unsupported content found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No empty-state or hedged ER passage is carried into the QRS in altered form; marker_4_target retains the ER’s “No established functional target” hedge verbatim (QRS line 637 / ER line 399). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications keep their ER force and thresholds, e.g. “Pregnancy and lactation (intakes above 2 g daily)” (QRS line 544) preserves the ER’s 2 g qualifier (ER line 298); “pending sterol measurement” retained (QRS line 545). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and Key Interactions both come from the ER Key Interactions & Contraindications section only; Benefits from Expected Benefits; Risks from Potential Risks & Side Effects. No modifying factors surfaced as gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, author names, NCT identifiers or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present beyond the fixed template AI4L link. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Lede mirrors the ER Conclusion register (“plant fat”, “gets in cholesterol’s way inside the gut”); body labels reuse ER wording. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric targets and dose ranges throughout; lede closes on the actionable screening test rather than a warning. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as labelled facts and ranges; no imperatives in the authored text. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol cells state ER regimens as descriptive labels/values; no instructions to the reader. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommend”, “advise”, “should” in the authored content. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Lede is free of technical terms; the clinical terms retained in the gates and monitoring table (sitosterolemia, macrothrombocytopenia, ABCG5/ABCG8) are load-bearing decision-gate precision carried from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and Risks reduced to tier-level noun phrases; interactions reduced to bare labels; lede at 59 words. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-file search for “you”/”your”; no hits. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Nine-marker monitoring table, baseline sterol screening and a defined cadence assume a self-tracking, proactive reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Divided dosing with meals, separated carotenoid intake and a repeat sterol panel are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes access to a non-cholesterol sterol panel and plasma carotenoid measurement — not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede foregrounds the single screening test that separates the harmless case from the harmful one, which is the decision-relevant point for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears in the title and header topic; no “anti-aging” anywhere in the file. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No lay route-of-administration or consumer-grade substitutions; “capsule”, “fortified spread”, “divided doses”, “plasma”, “serum” used throughout. The lede’s “plant fat” and “blood test” mirror the ER Conclusion (ER lines 433, 435). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All verified character-for-character against [qrs_template]: QRS lines 440, 477, 519, 570, 589, 708 (headings); 539, 550 (gates); 522, 525, 528, 531, 573, 576, 579, 582 (tiers); 593–595 (column headers). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 20 distinct template variable names present; the indexed families are expanded correctly (marker_1..9 × name/target/why, qualitative_item_1..6), plus action_1..3 and time_1..3 label/value/sub. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Non-variable template markup is byte-identical, including <span website="evidence_review">, <span website="audit">, <span website="full_review">, the footer disclaimer and the template’s “BENEFTIS” comment typo. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty; every tier, gate list and monitoring row has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard prostate protocol”, “Standard cholesterol protocol”, “Best time of day” match ER lines 320, 322, 326; all ten interaction labels match ER lines 273–291 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels (“Urinary symptoms”, “Cholesterol reduction”) are the ER’s own subjects from ER line 366; monitoring marker names match the ER Biomarker column exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⭕️ Not Central to Health & Longevity” and “⚠️ Conflicted” markers were correctly stripped (QRS lines 528, 576). |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: ER benefit/risk prose reduced to tier noun phrases, ten interaction bullets to bare labels, ER protocol trimmed to three cells, monitoring “Why” fields shortened (e.g. the ER’s “; fell about 29 mL in trials” dropped at QRS line 673). Unused time_3 cell is hidden rather than padded. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Single comment at QRS lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element echoes the block. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; the only quoted value is duration: "00:03", which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: beta_sitosterol_2026-0920-0013_Opus_ER.md, matching the ER’s own filename (ER line 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0920-0206, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: beta_sitosterol_2026-0920-0013_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including the tooling-added duration, git_user, git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS line 22: “Beta-Sitosterol for Health & Longevity - Quick Reference Sheet”; matches ER canonical_topic (ER line 8) with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS line 417: “Beta-Sitosterol for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS line 421: “09/20/2026” from qrs_creation_date: 2026-0920-0206. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS line 425: “Opus 5”, matching the frontmatter fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the template’s title and subline; the ER’s “Also known as” line (ER line 31) is correctly omitted. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | QRS line 433 compresses the ER Conclusion (ER lines 433–437): mechanism, the two supported effects with dose direction, tolerability, and the single pre-start blood measurement. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “gets in cholesterol’s way inside the gut” ← ER line 433; “falls modestly, rising with dose then levelling off” ← ER line 433; “much smaller doses ease the urinary complaints … without shrinking it” ← ER line 433; “Generally well tolerated” and “one blood test beforehand” ← ER line 435. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “plant sterols” rendered as “plant fats”, “benign prostatic hyperplasia” as “an enlarged prostate”, “LDL-C” as “blood cholesterol”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Direction only (“falls modestly”, “rising with dose then levelling off”); no percentages, mmol/L values or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items trace to the ER’s “Populations who should avoid Beta-Sitosterol” list (ER lines 293–300). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER populations present, in ER order (QRS lines 541–546). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Six <li> elements inside the stop_items span, nested in the template <ul>. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing ER rationales stripped: “where carotenoid depletion is judged unacceptable”, “where European food regulators advise against”, “where symptom relief delays definitive treatment” all removed; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “both copies of ABCG5/ABCG8”, “baseline plasma sitosterol above about 1 mg/dL”, “under 5 years”, “(intakes above 2 g daily)”, “pending sterol measurement”, “Untreated”/”acute” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is not empty; the ER names six populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items trace to the ER bullets at lines 273–291. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interaction bullets present in ER order; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements inside the caution_items span (QRS lines 552–561). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is the bare ER bold label; the ER’s “Monitor.”/”Caution.” verdicts and mechanistic sentences are all stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example lists preserved verbatim: “(atorvastatin, rosuvastatin, simvastatin)”, “(cholestyramine, colestipol, colesevelam)”, “(over-the-counter and prescription)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses; all parenthetical content is plain comma-separated drug lists. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is not empty; the ER names ten interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (ER lines 320, 322, 326). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two indication-specific dose regimens plus administration timing — the only three cells that determine how the compound is actually taken; the remaining ER bullets are modifiers rather than actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides at least three actionable aspects and all three sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables populated: “60–130 mg daily” / “Free β-sitosterol in two or three divided doses” (ER line 320); “1.6–3 g daily” / “Plant sterols in which β-sitosterol predominates; fortified spread, yoghurt drink or capsule” (ER line 322); “With meals” / “Fat is required; splitting across the two largest meals outperforms a single dose” (ER line 326). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER states exactly two time-to-effect aspects (ER line 366: cholesterol reduction, urinary symptom improvement); both are covered and the third set is correctly left unused per 11.3. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Urinary symptoms first, cholesterol second — matching the ER’s High-tier benefit ordering (ER lines 141, 147). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | The third pcell carries style="display: none" with all three spans empty (QRS lines 503–513); no placeholder or empty-state text. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “Urinary symptoms” / “From ~4 weeks” / “Full extent by 12–26 weeks in the trial data” and “Cholesterol reduction” / “2–3 weeks” / “Complete by four weeks” all trace to ER line 366. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items are the ER’s own benefit sub-headings (ER lines 141–187). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (QRS lines 521–532). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is a bare noun phrase; no IPSS points, percentages, confidence intervals or source attributions carried over from the ER’s Magnitude paragraphs. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefits item; the ER’s “⭕️ Not Central to Health & Longevity” marker on the alopecia item is stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have ER content, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items are the ER’s own risk sub-headings (ER lines 209–257). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (QRS lines 572–583). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare noun phrases only; the ER’s withdrawal rates, 16.3% carotenoid fall, µmol/L rises and source citations are all absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risks item; the ER’s “⚠️ Conflicted” marker on the circulating-sterol item is stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have ER content, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows and cadence derive from the ER Monitoring Protocol & Defining Success section (ER lines 392–404). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarker rows present in ER order: LDL cholesterol, total cholesterol, serum sitosterol, serum campesterol, PSA, IPSS, post-void residual volume, plasma β-carotene, complete blood count with platelet indices. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS line 702: “Lipid panel and symptom score at 8–12 weeks; sterol panel at 6 months; then every 6–12 months once values are stable” — matches the ER cadence sentence (ER line 392). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (ER lines 408–413). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present and in ER order (QRS lines 711–726). |
Issues 20/09/2026 02:16
Pass rate 100.00%. No issues found.
Issues 20/09/2026 02:08
- 1.2 — Campesterol caution dropped:
marker_4_target(QRS line 637) reads “Unchanged from personal baseline, within the assay reference range”, dropping the ER’s explicit caution “No established functional target” (ER line 399), so the row reads as though a target value existed.
Fixes 20/09/2026 02:08
- 1.2 — Campesterol caution restored:
marker_4_targetchanged from “Unchanged from personal baseline, within the assay reference range” to “No established functional target; unchanged from personal baseline, within the assay reference range”, restoring the ER’s explicit caution.